VP & Head of Antigen Business Unit at Valo Therapeutics
Otto is on a quest to enable the development of truly personalized therapeutics to fight cancer. He also supports academic researchers and startups in early-stage research commercialization and is building “rent-a-lab” facilities for biotech startups in the capital region. Otto Kari, Ph.D., is Vice President & Head of the Antigen Business Unit at Valo Therapeutics, a clinical-phase immuno-oncology company – and University of Helsinki spinout from 2016 – that develops transformative cancer immunotherapies. His team builds and deploys advanced technologies for antigen identification, including the innovative PeptiCHIP microchip technology that recently received a European Innovation Council Transition grant.
Otto is also Laboratory Director for PharmaHUB & Viikki Business Labs at the University of Helsinki, Chair of the Council at the Finnish Red Cross, and advisor to SPARK Finland. He has >15 years of experience in pharmaceutical research and development, with advanced qualifications in R&D and technology management. He has authored 13 peer-reviewed articles covering fields such as cancer immunotherapy, pharmaceutical nanotechnology, and drug delivery. He received the Albert Wuokko Award 2022 in recognition of his contributions to pharmaceutical sciences as a young researcher.